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ABSTRACT
Ataxia-telangiectasia mutated (ATM) is a cell cycle checkpoint kinase that upon 
activation by DNA damage leads to cell cycle arrest and DNA repair or apoptosis. The 
absence of Atm or the occurrence of loss-of-function mutations in Atm predisposes 
to tumorigenesis. MAPK7 has been implicated in numerous types of cancer with pro-
survival and pro-growth roles in tumor cells, but its functional relation with tumor 
suppressors is not clear. In this study, we show that absence of MAPK7 delays 
death due to spontaneous tumor development in Atm-/- mice. Compared with Atm-
/- thymocytes, Mapk7-/-Atm-/- thymocytes exhibited an improved response to DNA 
damage (increased phosphorylation of H2AX) and a restored apoptotic response 
after treatment of mice with ionizing radiation. These findings define an antagonistic 
function of ATM and MAPK7 in the thymocyte response to DNA damage, and suggest 
that the lack of MAPK7 inhibits thymic lymphoma growth in Atm-/- mice by partially 
restoring the DNA damage response in thymocytes.
INTRODUCTION
ATM is a serine/threonine protein kinase that is 
rapidly activated by several stressors including nuclear 
replication stress [1], oxidative stress [2] [3] and 
mitochondrial dysfunction [4] [5]. Activation of ATM by 
DNA damage triggers cell cycle checkpoints, including 
G1/S and G2/M [6] [7], and DNA repair or apoptosis, 
preventing the transmission of mutations to daughter cells. 
The absence of ATM in humans and mice increases the 
incidence of tumors of predominantly lymphoid origin, 
with most tumors appearing in Atm-/- mice being thymic 
lymphomas [8] [9]. 
MAPK7 (also named ERK5) is a member of the 
mammalian mitogen-activated protein kinase family with 
a kinase domain homologous to that of MAPK3 (ERK1) 
and MAPK1 (ERK2), and a unique C-terminal domain 
that determines its cellular location and activity [10]. 
Deletion of Mapk7 in mice leads to embryonic lethality 
due to defective vascular and cardiac development [11-
13]. MAPK7 controls the expression of genes that regulate 
angiogenesis and cardiovascular development [14], is 
necessary for endothelial homeostasis [15] [16] and 
contributes to B-cell survival [17] and erythropoiesis in 
mice [18].
MAPK7 is deregulated in numerous types of cancer 
[19], including lymphoma [20]. MAPK7 may also mediate 
chronic inflammation-dependent tumorigenesis in the skin 
[21] [22]. The tumorigenicity of MAPK7 has been related 
to its capacity to interact with promyelocytic leukemia 
protein and inhibit its tumor suppressor activity [23]. By 
blocking the interaction of promyelocytic leukemia protein 
with MDM2, active MAPK7 might facilitate the inhibition 
of tumor suppressor p53 by MDM2 [24]. Based on the use 
of the MAPK7 inhibitor XMD8-92, it has been shown that 
MAPK7-dependent inhibition of p53 contributes to tumor 
growth in a xenograft model [23] [24], though XMD8-92 
could have another cellular target besides MAPK7 [25]. 
In contrast to the role of ATM in triggering cell 
cycle checkpoints upon DNA damage, MAPK7 activity 
peaks at G2/M and is required for progression through 
this cell cycle phase [26]. The data describing opposing 
roles of ATM and MAPK7 in cell cycle regulation and 
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tumor growth suggest that these could be functionally 
linked. To test this hypothesis, and as Atm-/- mice show a 
strong predisposition to thymic lymphomas, we eliminated 
MAPK7 in the hematopoietic system of Atm-/- mice and 
assessed the time of tumor appearance. This approach can 
yield information on the role played by MAPK7 during 
the spontaneous progression of a cell toward malignancy. 
We show that loss of Mapk7 in the hematopoietic system 
of Atm-/- mice increases the DNA damage response in 
thymocytes and delays death by spontaneous tumor 
development in Atm-/- mice.
RESULTS
Absence of MAPK7 in the hematopoietic system 
delays death by spontaneous tumor development 
in Atm-/- mice
To determine whether Mapk7 and Atm are 
functionally linked in tumorigenesis, and given that 
Atm-/- mice spontaneously develop thymic lymphomas, 
we removed Mapk7 in the hematopoietic system of 
Atm-/- mice, and assessed the spontaneous rate of tumor 
development in Atm-/- and in Atm/Mapk7-double null 
mice. To this end, Atm+/- mice were crossed to Mapk7loxP/
loxPvav-cre mice (hereafter referred to as Mapk7hemat-/- 
mice; Supplementary Figure 1), which lack Mapk7 in 
hematopoietic cells [27] [28] or to control Mapk7loxP/
loxP mice (referred to as wild-type mice), and double 
heterozygous F1 progeny were crossed to obtain F2 
Mapk7hemat-/-Atm-/- mice and Mapk7loxP/loxPAtm-/- mice 
(referred to as Atm-/- mice). 
Most Mapk7hemat-/-Atm-/- mice grew to adulthood and 
showed the low body weight characteristic of Atm-/- mice 
(data not shown). Genotyping of young offspring from 11 
(Mapk7hemat-/-Atm+/-) x (Mapk7loxP/loxPAtm+/-) crosses and 9 
Mapk7hemat-/-Atm+/- mice intercrosses revealed no statistical 
differences in the frequency of mice homozygous for Atm 
(p = 0.35 by chi-squared analysis) as compared with the 
expected Mendelian frequency (Supplementary Figure 
2). However, mice with null homozygosis for both Atm 
and Mapk7 were born at a lower frequency than expected 
Figure 1: Absence of MAPK7 delays tumorigenesis in Atm-/- mice. A. Kaplan-Meier survival curves of Mapk7hemat-/- (n = 33), Atm-
/- (n = 22) and Mapk7hemat-/-Atm-/- (n = 24) mice over 320 days. P values were obtained by the log-rank test. B. Total cellularity of wild-type 
(n ≥ 5), Mapk7hemat-/- (n = 7), Atm-/- (n = 7) and Mapk7hemat-/-Atm-/- (n ≥ 8), in the indicated organs. 
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(p = 0.024), suggesting that the absence of both genes 
in the hematopoietic system produces a developmental 
drawback. However, the possibility that it is the presence 
of Cre recombinase, rather than the absence of MAPK7 
what affects the birth rate of Atm-/- mice cannot be 
excluded. 
We then assessed the survival of these adult mice. 
In agreement with previous studies, we did not observe 
spontaneous tumor formation in Mapk7hemat-/- mice [17] 
[18] [27] [29] and no mice died during the first year of 
life (Figure 1A). In contrast, the median survival time of 
Atm-/- mice was 153 days of age (Figure 1A) with ~80% of 
these mice having died at 300 days of age. Interestingly, 
the median survival time of Mapk7hemat-/-Atm-/- mice was 
281 days of age (Figure 1A). Thus, Mapk7hemat-/-Atm-/- mice 
showed a significant increase in survival compared to Atm-
/- mice (p = 0.02 at day 320, log-rank test), indicating that 
MAPK7 deficiency in the hematopoietic system delays 
death by spontaneous tumor development in Atm-/- mice 
and suggesting an antagonistic interaction between the 
MAPK7- and ATM-signaling pathways affecting thymic 
lymphoma development.
Most tumors appearing in Atm-/- and Mapk7hemat-
/-Atm-/- mice were thymic lymphomas. However, older 
mice (~1 year or more) presented tumors of different 
types or died of unknown causes associated with a wasting 
syndrome (Supplementary Table I). The longer survival 
of Mapk7hemat-/-Atm-/- mice might facilitate the emergence 
of other disorders linked to the absence of ATM [30]. 
The thymic tumor cells were clonal, showed either an 
immature phenotype with a CD4+CD8+ signature or were 
single-positive (SP) thymocytes (Supplementary Figure 
3). 
Figure 2: Normal erythropoiesis in Mapk7hemat-/-Atm-/- mice and impaired B cell development in Atm-/- and Mapk7hemat-/-
Atm-/- mice. A. Representative flow cytometry profiles representing the erythroid population in the bone marrow. Dot plots representing 
erythroid precursor distribution based on ter119 and CD71 expression (top). Percentage of ter119+ population in wild-type (n = 3), Mapk7hemat-/- 
(n = 7), Atm-/- (n = 3) and Mapk7hemat-/-Atm-/- (n = 6) bone marrow (bottom). B. Representative flow cytometry profiles representing B cell 
precursor distribution (B220lowIgM-, B220lowIgM+, B220highIgM+) in the bone marrow population (top). Percentage of bone marrow B cell 
precursors in wild-type (n = 3), Mapk7hemat-/- (n = 7), Atm-/- (n = 3) and Mapk7hemat-/-Atm-/- (n = 6) mice.
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Normal erythropoiesis in Mapk7hemat-/-Atm-/- mice 
and impaired B cell development in Atm-/- and 
Mapk7hemat-/-Atm-/-mice
Some hematopoietic-specific traits of Atm-/- mice, 
such as reduced thymocyte cellularity, were also evident 
in Mapk7hemat-/-Atm-/- mice, whereas Mapk7hemat-/- mice 
presented a small increase (Figure 1B). Interestingly, Atm-/- 
mice, but not Mapk7hemat-/-Atm-/- mice, showed also reduced 
cellularity in the bone marrow and spleen. Absence of Atm 
or Mapk7 leads to hematopoietic impairment [17] [18] 
[30], we therefore analyzed in more detail the erythroid 
and B cell development in the bone marrow in 4- to 
8-week-old mice. 
The generation of erythropoietic precursors 
(cells CD71+ter119+) diminished in the bone marrow of 
Mapk7hemat-/- mice but not in Atm-/- mice (Figure 2A) [18]. 
Interestingly, the erythropoiesis impairment observed in 
Mapk7hemat-/- mice disappeared in Mapk7hemat-/-Atm-/- mice, 
indicating that the absence of Atm compensates for the 
absence of Mapk7 during erythropoiesis in bone marrow 
of young mice (Figure 2A, bottom).
The analysis of B cell progenitors in the bone 
marrow showed that generation of the B cell precursor 
B220lowIgM+ was impaired in the three genotypes: 
Mapk7hemat-/-, Atm-/- and Mapk7hemat-/-Atm-/- mice (Figure 2B) 
[17] [18]. Moreover, the generation of the B cell precursor 
B220highIgM+ was also impaired in Mapk7hemat-/- and 
Figure 3: Equivalent thymic cellular distribution in Atm-/- and Mapk7hemat-/-Atm-/- mice. A. Representative flow cytometry 
profiles representing thymic cell distribution based on CD4 and CD8 expression (top). Percentage of thymic cell subsets (bottom). 
Thymocytes were isolated from 4- or 5-week-old wild-type (n = 6), Mapk7hemat-/- (n = 7), Atm-/- (n = 7) and Mapk7hemat-/-Atm-/- (n = 8) mice, 
stained with anti-CD4-APC and anti-CD8-FITC, and then analyzed by flow cytometry. Data represent mean +/- SD of CD4-CD8- DN, 
CD4+CD8+ DP and SP CD4+ and CD8+ cell subsets. B. Number of thymocytes in each developmental stage, for the same mice analyzed 
in A.. C. Representative flow cytometry profiles of thymic DN population based on CD44 and CD25 expression (top). Percentage of DN 
thymocyte cell subsets (bottom). Thymocytes were isolated from 4- and 5-week-old wild-type (n = 6), Mapk7hemat-/- (n = 7), Atm-/- (n = 7) and 
Mapk7hemat-/-Atm-/- (n = 8) mice, stained with anti-CD4-APC, anti-CD8-alexa 488, anti-CD44-PerCP and anti-CD25-PE, and then analyzed 
by flow cytometry. Data represent mean +/- SD of CD44+CD25- (DN1), CD44+CD25+ (DN2), CD44-CD25+ (DN3) and CD44-CD25- (DN4) 
subsets. D. Number of thymocytes in each DN cell subset for the same mice analyzed in C..
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Mapk7hemat-/-Atm-/- mice. The combined absence of Mapk7 
and Atm did not have an additive effect on decreasing 
further the bone marrow B220lowIgM+ or B220highIgM+ 
pools.
In the lymph nodes and spleen, the percentage of 
mature B cells was not affected by the absence of Atm 
and/or Mapk7. Regarding T cells, while CD8+ T cells 
were not altered, a decrease in the percentage of CD4+ 
T cells was observed in the lymph nodes of Atm-/- mice 
and in the spleen of mice lacking both Mapk7 and Atm 
(Supplementary Figure 4).
These results indicate that these two kinases play a 
different role in erythroid and B cell development, with 
both kinases contributing to B cell development, but only 
Mapk7 being necessary for normal erythroid development 
in young mice.
Equivalent thymic cellular distribution in Atm-/- 
and Mapk7hemat-/-Atm-/- mice
We then assessed whether Mapk7 and Atm are 
functionally linked during T cell development, by 
performing a flow cytometry analysis on thymocytes 
isolated from 4- or 5-week-old mice. The percentage of SP 
CD4+ thymocytes decreased in mice strains lacking Atm, 
whereas the percentage of CD4-CD8- double-negative 
(DN), CD4+CD8+ double-positive (DP) and SP CD8+ 
thymocytes did not change (Figure 3A) [9] [31]. When 
the absolute cell numbers were considered, the DP and SP 
CD4+ thymocytes decreased in mice strains lacking Atm 
(Figure 3B) [31]. Atm-/- mice and Mapk7hemat-/-Atm-/- mice 
presented a similar number of DN, DP and SP thymocytes 
(Figure 3B).
Thymocytes at DN stage start the recombination 
of V(D)J gene segments, a process that ends at the DP 
stage and requires the activity of ATM for proper repair 
of the DNA double-strand breaks (DSB) produced during 
DNA recombination [31] [32]. The lower number of DP 
and mature SP CD4+ thymocytes in mice strains lacking 
Atm suggests that a partial arrest of thymocyte maturation 
during the DN stage is taking place in these mice, probably 
as a result of the incapacity to resolve the DSB generated 
during DNA recombination [33]. 
As the main proliferative population, the DN 
thymocytes were analyzed in more detail. The DN pool 
can be fractionated in progressively maturing DN1 to 
DN4 subsets according to the expression of the IL-2 
receptor alpha chain (CD25) and CD44 (Figure 3C, 
3D). Thymocyte precursors initiate the recombination 
of tcrg, tcrd and tcrb mainly at the CD4−CD8−CD44−
CD25+ (DN3) stage, and completion of this process and 
expression of pre-TCR leads to differentiation into CD4−
CD8−CD44−CD25− (DN4) cells. Neither the percentage 
of DN populations nor the number of cells in each DN 
pool did show differences between wild-type and the 
other genotypes, or between Atm-/- mice and Mapk7hemat-
/-Atm-/- mice (Figure 3C, 3D). Only Mapk7hemat-/- mice and 
Mapk7hemat-/-Atm-/- mice did show a different number of 
CD4−CD8−CD44+CD25- (DN1) and DN4 cells (Figure 
3D).
Taken together, these results indicate that deletion 
of Mapk7 in Atm-/- mice did not change the distribution of 
major thymic populations.
Increased G2/M cell cycle phase accumulation in 
DN thymocytes of Mapk7hemat-/-Atm-/- mice
Although no major changes between the thymocyte 
distribution of 4- to 5-week old Atm-/- mice and Mapk7hemat-
/-Atm-/- mice could be found, the delay in thymic lymphoma 
development in the latter suggest that the proliferative 
capacity of thymocytes or their apoptotic response to 
DNA damage has changed. Cell cycle distribution was 
assessed in total thymocytes, and a significant increase 
in G2/M fraction in Mapk7hemat-/-Atm-/- mice was observed 
in comparison to wild-type mice (Supplementary Figure 
5A). As Atm-/- thymocytes fail to progress through the 
DN3 stage [33] and DN thymocytes are the thymic 
population with proliferative activity, we analyzed the 
cell cycle distribution of DN thymocytes. Interestingly, 
DN thymocytes from Mapk7hemat-/-Atm-/- mice presented a 
higher percentage of cells in the G2/M-phase of the cell 
cycle (Figure 4A). Besides DN thymocytes, no differences 
in cell cycle distribution were detected among the different 
genotypes in DP, CD4+ SP and CD8+ SP thymocyte 
subsets (Suplementary Figure 5B), indicating a specific 
effect of the combined deficiency of Mapk7 and Atm in 
DN thymocyte proliferation. The increase in the G2/M 
fraction of DN thymocytes in Mapk7hemat-/-Atm-/- mice did 
not increase the number of DN cells (Figure 3), suggesting 
that the lack of Mapk7 in Atm-/- DN thymocytes could be 
inducing a partial G2/M arrest or an increase in thymocyte 
apoptosis in these mice. We were unable to detect changes 
in apoptosis, as analyzed by annexin V staining, which 
was similar in the three genotypes investigated (Figure 
4B).
In addition to a deficit in the DNA damage response, 
the absence of Atm leads to mitochondrial dysfunction and 
oxidative stress [34] [35]. In order to ascertain whether the 
delay in thymic lymphoma growth observed in Mapk7hemat-
/-Atm-/- mice was also related to changes in mitochondrial 
function, we analyzed the mitochondrial content and 
membrane potential in thymocytes. No major differences 
were observed between Atm-/- and Mapk7hemat-/-Atm-/- 
mice in mitochondrial content or membrane potential 
(Figure 4C). Furthermore and related to the alterations 
in mitochondria, Atm-/- mice of approximately 6 months 
of age have been described to exhibit an increase in 
reactive oxygen species (ROS) [30]. Quantitation of ROS 
in thymocytes of 4- to 5-week old mice by staining with 
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dihydrorhodamine-123 did not show major differences 
between control Mapk7hemat-/-, Atm-/- and Mapk7hemat-/-
Atm-/- mice (Figure 4C). These results suggest that neither 
differences in mitochondrial activity nor ROS content 
were responsible for the delay in thymic lymphoma 
observed in Mapk7hemat-/-Atm-/- mice.
Absence of Mapk7hemat-/-Atm-/- mice restores the 
DNA damage response to ionizing radiation
Tumor susceptibility in Atm-/- mice is caused by 
deficiencies in the DNA damage response; therefore, we 
investigated the effect of Mapk7 loss on DNA damage 
signaling. The DSB caused by ionizing radiation activate 
ATM, which phosphorylates several key participants in the 
DNA damage response, including histone H2AX, which 
enables recruitment of DNA repair complexes [36] [37]. 
Exposure of control Mapk7hemat-/- mice to 6-Gy ionizing 
radiation led to phosphorylation of H2AX, indicating the 
presence of DNA damage in thymocytes harvested 2 hours 
after the mice were exposed to radiation (Figure 5A). 
However, thymocytes isolated from irradiated Atm-/- mice 
showed a deficit in this signaling response (Figure 5A), 
consistent with published data [38]. Conversely, loss of 
Figure 4: Increased G2/M cell cycle phase accumulation in DN thymocytes of Mapk7hemat-/-Atm-/- mice. A. Representative 
flow cytometry profiles of DNA content in DN thymocytes based on Hoechst staining (top). Percentage of DN thymocytes in each cell cycle 
phase (bottom). Thymocytes were fixed in 1% paraformaldehyde, labeled with anti-CD4 and anti-CD8 antibodies as indicated in Figure 3 
and stained with Hoechst 33342. B. Percentage of live thymocytes measured immediately after thymic extraction. Representative dot plots 
(left); quantification of FACS staining (right, n ≥ 3 for each genotype). Apoptosis was measured by staining with annexin V and DAPI 
followed by flow cytometry analysis. C. The mitochondrial mass, membrane potential and cellular ROS in thymocytes were determined by 
staining with mitoTracker-green, mitoTracker-red and dihydrorhodamine-123, respectively, and analyzed by flow cytometry (n ≥ 3 for each 
genotype). The MFI in arbitrary units is shown.
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Mapk7 in Atm-/- mice restored the capacity of thymocytes 
to respond to DNA damage caused by ionizing radiation, 
via phosphorylation of H2AX (Figure 5A). In untreated 
mice, phosphorylation of H2AX in thymocytes presented 
no differences between the different genotypes. These 
results indicate that the deficient DNA damage response 
in Atm-/- mice can be restored by loss of Mapk7. 
Phosphorylation of H2AX promotes the recruitment 
of checkpoint proteins and initiation of the G2/M 
checkpoint [39]. We therefore determined the cell cycle 
phases in thymocytes from irradiated mice. Ionizing 
radiation did not induce a change in the cell cycle profile 
of Atm-/- thymocytes, indicating radioresistant DNA 
synthesis (Figure 5B) [40] [41]. Interestingly, thymocytes 
from irradiated Mapk7hemat-/-Atm-/- mice showed a partial 
G2/M arrest (Figure 5B). This indicates that in Atm-
/- thymocytes, the presence of MAPK7 inhibited the 
G2/M checkpoint triggered by radiation-dependent DNA 
damage, and this G2/M checkpoint was partially restored 
in Mapk7hemat-/-Atm-/- thymocytes. 
Figure 5: Absence of Mapk7 in Atm-/- mice restores the DNA damage response to ionizing irradiation. Mice were treated 
with 6 Gy and two hours later, thymocytes were isolated and lysed in SDS-buffer or fixed for cell cycle analysis. A. Phosphorylation of 
H2AX (pH2AX) in thymocytes isolated from irradiated (IR) mice. Representative Western blot with pH2AX and tubulin as loading control 
(left); pH2AX:tubulin ratio normalized to control Mapk7hemat-/- (right; n ≥ 3 for each genotype). n.s., not significant. B. Cell cycle distribution 
of live thymocytes isolated from the same mice evaluated in A., as analyzed by PI staining. C. Cell death of the same thymocyte samples 
evaluated in B. (sub-G1 fraction). D. Representative flow cytometry profiles of DNA content in thymocytes based on PI staining. The 
quantitation of these results is represented in B. for live thymocytes and in C. for dead cells.
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As anticipated, irradiation of control Mapk7hemat-/- 
mice provoked an early massive apoptosis of thymocytes 
(Figure 5C). Although the early apoptotic response of 
thymocytes from irradiated Atm-/- mice and Mapk7hemat-
/-Atm-/-mice was similar (Figure 5C, 5D), we further 
examined the apoptosis of these cells after culturing 
them at 37ºC for 20h and staining them with annexin 
V and DAPI. Whereas the survival of irradiated control 
Mapk7hemat-/- thymocytes was markedly low, a substantial 
percentage of thymocytes from Atm-/- mice survived after 
mice irradiation and cell culture (Figure 6). Importantly, 
the loss of Mapk7 in Atm-/- mice partially restored the 
apoptotic response of thymocytes to DNA damage (Figure 
6). Taken together, these results indicate that loss of Mapk7 
in Atm-/- mice restores the DNA damage-signaling pathway 
in thymocytes, leading to G2/M arrest and apoptosis when 
mice are subjected to irradiation.
Human cancers with ATM mutations do not show 
increased Mapk7 mRNA content
The data presented above suggest that in absence of 
Atm, an increase in the expression or function of MAPK7 
could be advantageous for oncogenic transformation. To 
test this hypothesis, we queried The Cancer Genome Atlas 
(TCGA) clinical database for the expression of MAPK7 
mRNA in human cancers presenting mutated ATM. The 
results indicate that there is not a statistically significant 
relationship between the presence of ATM mutations and 
Figure 6: Absence of Mapk7 in Atm-/- mice restores the apoptotic response to ionizing irradiation. Percentage of live 
thymocytes after isolation from irradiated mice (6 Gy) and culturing for 20 h. Representative flow cytometry profiles A. and quantification 
of FACS staining (percentage of live cells) B.. Cell death was measured by staining with annexin V and DAPI followed by flow cytometry 
(n ≥ 3 for each genotype). n.s., not significant.
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MAPK7 mRNA content in human cancer (Supplementary 
Figure 6).
DISCUSSION
ATM is activated by DNA damage and is necessary 
during T cell development to repair DSB generated during 
Tcr recombination [32]. Developing T cells in Atm-/- mice 
present unprotected DNA ends that recombine abnormally 
[42], leading to immunodeficiency and genetic instability, 
and ultimately this can provoke T cell lymphoma. 
However, Atm-/- mice lacking recombinase activating 
genes are free of tumors [43].
In this study, we have shown that the loss of Mapk7 
in Atm-/- mice delays tumorigenesis, indicating a functional 
interaction between Mapk7 and Atm. Upon DNA damage, 
ATM phosphorylates several key participants in the 
DNA damage response, including H2AX, which enables 
recruitment of DNA repair complexes [44] and the 
arrest of DNA replication. In contrast, Atm-/- cells show 
impaired H2AX phosphorylation and radioresistant DNA 
replication (the present study) [40] [41]. The results from 
irradiated mice reported here indicate that when Mapk7 
is eliminated in Atm-/- mice, H2AX phosphorylation is 
restored, together with partial G2/M arrest and increased 
apoptosis of thymocytes. The phosphorylation of H2AX 
in Mapk7hemat-/-Atm-/- thymocytes is probably responsible 
for restitution of the G2/M checkpoint [39]. The reported 
activities of MAPK7 related to cell cycle control include 
its increased activity at G2/M, facilitating this cell cycle 
transition [26]. Loss of Mapk7 might result in stronger 
activation of the G2/M checkpoint upon DNA damage, 
as observed in the present study. Restoration of the DNA 
damage response and the G2/M checkpoint in Mapk7hemat-
/-Atm-/- thymocytes reduces the generation of DNA 
instability and probably contributes to the delay of thymic 
lymphoma in Mapk7hemat-/-Atm-/- mice. 
During the V(D)J recombination process, ATM, 
DNA-PKc and H2AX function in a common DNA repair 
pathway [45]. ATM regulates hairpin-sealed DNA end-
processing by phosphorylation of DNA-PKc [46], whereas 
H2AX has a specific role in preservation of the structural 
integrity of broken DNA ends during V(D)J recombination 
in murine lymphocytes [47]. The phosphorylation of 
H2AX in cells under ionizing radiation is mediated by both 
ATM and DNA-PKc [48]. Therefore, the phosphorylation 
of H2AX in thymocytes from irradiated Mapk7hemat-/-Atm-/- 
mice, but not from irradiated Atm-/- mice, suggests that 
in absence of ATM, MAPK7 inhibits DNA-PKc. These 
data suggest that a normal function of MAPK7, regulated 
by ATM, may be to inhibit DNA-PKc kinase activity in 
DN thymocytes, reducing the DNA damage response and 
apoptosis during tcr recombination. If unrestrained by 
ATM, this MAPK7 activity in developing T cells could 
therefore lead to genetic instability. 
Due to damaged DNA, Atm-/- thymocytes cannot 
mature efficiently and their number diminish after the DN 
stage, showing a shortage of DP and maturing SP CD4+ T 
thymocytes (the present study and [9]). Restitution of the 
DNA damage response in Mapk7hemat-/-Atm-/- thymocytes 
did not alleviate arrest at the DN stage, suggesting that 
although undetected, increased apoptosis of potentially 
oncogenic DN thymocytes in Mapk7hemat-/-Atm-/- mice 
contributes to delaying thymic lymphoma development. 
We have recently reported that MAPK7 is necessary 
for normal erythropoiesis in mice, contributing to proper 
dNTP metabolism in highly proliferative erythroid 
progenitors [18]. Loss of Mapk7 in the hematopoietic 
compartment gives rise to extramedullary erythropoiesis, 
splenomegaly and an increased mutation rate in 
erythrocyte precursors, probably due to an imbalance of 
dNTPs [18]. Contrary to Mapk7hemat-/- mice, erythropoiesis 
was restored in the bone marrow of Mapk7hemat-/-Atm-/- 
mice (the present study), indicating that the absence 
of Atm compensates for the absence of Mapk7 during 
erythropoiesis in young mice, and suggesting that the 
erythroid dNTP pool is normalized in Mapk7hemat-/-Atm-/- 
mice. This is consistent with increased cellular dNTP 
levels during replication stress in Atm-/- mice [49]. 
B cell development in the bone marrow was 
impaired in the three genotypes studied here, though the 
spleen and lymph nodes contained a normal number of 
mature B cells. MAPK7 is necessary in B cells to signal 
BAFF-surviving stimuli [17], whereas in Atm-/- mice the 
impairment in B cell development is related to a deficient 
V(D)J recombination [50]. Curiously, Mapk7hemat-/-
Atm-/- mice did not show a stronger alteration of B cell 
precursors, suggesting that both genes are acting through 
the same pathway. 
In addition to its role in the DDR response, 
ATM is activated by oxidative stress and is needed 
to maintain cellular homeostasis in front of oxidative 
and mitochondrial stressors [2-5] [30]. In the present 
study, we analyzed whether Atm-/- thymocytes presented 
evidences of oxidative and mitochondrial stress, but no 
alterations were observed. We hypothesize that a reason 
why no dysfunctions were detected is that our study on 
oxidative and mitochondrial activity was carried out 
with thymocytes from 4- to 5-week-old mice, which 
were younger than the ones used in other studies [5]. 
In addition, the genetic background of mice used in the 
present study could lie behind the apparent mitochondrial 
normality of Atm-/- thymocytes [51]. 
In an attempt to confirm that the development 
of cancer in absence of Atm is favoured by MAPK7 
function, we examined the MAPK7 mRNA content in 
human cancers presenting ATM mutations. However, no 
statistically significant relationship was found between the 
amount of MAPK7 mRNA and the presence of mutated 
ATM. These data do not confirm that MAPK7 provides an 
advantage to ATM-dependent tumorigenesis, though they 
do not formally exclude this possibility. MAPK7 function 
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could be beneficial to the oncogenic process when this is 
initiated by a particular type of ATM mutation. In addition, 
although we used mRNA data, the mRNA content and 
the activity of the expressed MAPK7 are distantly 
related. Therefore, the prospect of using functional data 
(i.e. MAPK7 activity) will provide a closer view to the 
MAPK7 - ATM relationship in human cancer.
Taken together, these data establish a functional 
relationship between Atm and Mapk7 during bone 
marrow erythropoiesis and suggest a non-redundant role 
of MAPK7 in thymic precursors during repair of tcr 
recombination-dependent DSB, facilitating mitigation 
of an excessive DNA damage response and apoptosis. In 
absence of MAPK7, thymocytes from irradiated Atm-/- 
mice partially recover the G2/M checkpoint, progress with 
increased difficulty through cell cycle and ultimately show 
increased apoptosis. These results suggest that MAPK7 
inhibitors could be of therapeutic value in lymphoma 
caused by absence of ATM by re-establishing cell cycle 
checkpoints in cancer cells.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance 
with the ethical standards and according to national and 
international guidelines and has been approved by the 
authors’ institutional review board (the Departament 
d’Agricultura, Ramaderia, Pesca, Alimentació i Medi 
Natural of Generalitat de Catalunya).
Mice
Atm+l- mice were kindly provided by Óscar 
Fernández-Capetillo (National Cancer Research Centre, 
Madrid, Spain) [52]. Mapk7loxP/loxP mice were kindly 
provided by Cathy Tournier (University of Manchester, 
Manchester, U.K.) [29]. Mapk7loxP/loxPvav-cre mice which 
lack Mapk7 in hematopoietic cells are described elsewhere 
[27] [28]. Mapk7loxP/loxPvav-cre mice were on C57BL/6 
background whereas Atm+/- mice had a mixed background 
(129S6, CD-1, C57BL/6). Atm+/- mice were crossed to 
Mapk7loxP/loxPvav-cre mice (referred to as Mapk7hemat-/-mice) 
or to control Mapk7loxP/loxP mice (referred to as wild-type 
mice), and double heterozygous F1 progeny were crossed 
to obtain F2 Mapk7hemat-/-Atm-/- mice and Mapk7loxP/loxPAtm-/- 
mice (referred to as Atm-/- mice). The Mapk7hemat-/- mice and 
wild-type mice, used in experiments were F1 crossings, in 
order to keep the same genetic background for all mice. 
Experiments were conducted on 4- to 8-week-old mice. To 
genotype mice, the following oligonucleotides were used: 
to detect floxed Mapk7, forward 5’-tccatgctgttagtcctttgg-3’ 
and reverse 5’-agcggctgtgaagagtgaat-3’ (floxed amplicon 
= 260bp, wild-type amplicon = 200bp). Presence 
of Vav-Cre was analyzed with the oligonucleotides: 
forward 5’-cgagtgatgaggttcgcaag-3’ and reverse 
5’-atcttcaggttctgcgggaa-3’. Wild-type Atm was detected 
with oligonucleotides: forward 5’-gctgccatacttgatccatg-3’ 
and reverse 5’- tccgaatttgcaggagttg-3’ (wild-type 
amplicon = 147bp). To detect neomycin gene insertion 
in Atm the following oligonucleotides were used: 
forward 5’-cttgggtggagaggctattc-3’ and reverse 
5’-aggtgagatgacaggagatc-3’ (neomycin amplicon = 
280bp). 
Cell culture and reagents
For cell preparations, single cell suspensions were 
isolated from thymus, spleen and bone marrow of mice. 
The suspension was counted to determine the organ 
cellularity, and then mature red blood cells of spleen 
and bone marrow suspensions were discarded from the 
suspension by overlaying cells on a solution of 16% 
iodixanol, 0.63% NaCl and 10 mM Hepes and centrifuged 
at 900x g for 30 minutes. The mononuclear fraction of 
the density gradient was collected, washed with PBS, 
counted and stained or fixed. Cell preparations were 
cultured in RPMI 1640 medium (ref. BE12-702F, Lonza) 
supplemented with 9% FBS, penicillin/streptomycin, 
2 mM L-glutamine. Mitotracker Green or Red (Life 
Technologies) was used at a concentration of 50nM for 15 
to 30 minutes at 37ºC.
Western blot
Cells were lysed in Laemmli buffer and loaded on 
10% or 15% acrylamide gels. Transfer to nitrocellulose 
membranes and immunoblotting was performed as 
previously described [18]. Incubation with primary 
antibody (mouse anti-H2AX phosphorylated S139, 
Biolegend #613401; rabbit anti-ERK5, Cell Signaling 
#3372; mouse anti-beta actin, Sigma-Aldrich #A2228; 
mouse anti-tubulin, Sigma-Aldrich #T9026) was 
performed overnight at 4ºC under agitation. The following 
day, after washing, the membrane was incubated with the 
secondary antibody-HRP conjugated (rabbit anti-mouse, 
Sigma-Aldrich #A9044; goat anti-rabbit, Sigma-Aldrich 
#A0545) for 1 hour under agitation at room temperature. 
Western blots were quantified on a Luminescent Image 
Analyzer LAS-3000 (Fujifilm). Densitometry analysis was 
performed using ImageJ software.
Immunostaining and flow cytometry analysis
For extracellular labeling, thymocytes, splenocytes, 
lymph node cells and bone marrow cells were stained 
with saturating amounts of primary antibodies conjugated 
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to fluorochromes (anti-CD4 APC, Biolegend #100516; 
anti-CD8 AlexaFluor 488, Biolegend #100706; anti-
CD44 PerCP, Biolegend #103032; anti-CD25 PE, 
Immunotools #22150254; anti CD71 PE, BD #553267; 
anti-Ter119 FITC, Biolegend #116205; anti-B220 FITC, 
Immunotools #22159453; anti-IgM PerCP, Santa Cruz 
#sc-45105) in PBS + 2% FBS for 25 minutes at 4ºC. Cells 
were then washed with PBS and analyzed using a Gallios 
flow cytometer (Beckman Coulter, Inc., Fullerton, CA). 
4’,6-diamidino-2-phenylindole (DAPI) was added to the 
samples in order to discard the dead cells. Changes in 
the mitochondrial mass, membrane potential and cellular 
ROS were determined by incubating the cells for 30 
min at 37ºC with mitoTracker-green, mitoTracker-red 
or dihydrorhodamine-123, respectively, and analyzed 
by flow cytometry. The mean fluorescence intensity 
(MFI) was represented. Fluorescence was collected on 
the logarithmic scale. The cell population was selected 
by gating in a forward scatter vs. side scatter dot plot, 
excluding aggregates and cell debris, and by excluding 
the DAPI-positive population.
Cell cycle analysis
In order to determine the cell cycle of irradiated 
thymocytes, 1*106 cells were fixed in 70% ethanol and 
stored at -20ºC. Samples were washed once with PBS 
and incubated in 0.1% triton X100, 0.02% RNAse A and 
0.0005% propidium iodide (PI) in PBS for 30 minutes 
at room temperature in the dark. Samples were analyzed 
in a Coulter XL cytometer and a subsequent cell cycle 
profile analysis was performed using cytomation summit 
software.
For cell cycle analysis of thymocyte subsets, 1*106 
cells were fixed in 1% paraformaldehyde, and stained with 
anti-CD4 and anti-CD8 antibodies for 30 minutes at 4ºC. 
Cells were then washed with PBS and incubated for 30 
minutes at room temperature with Hoescht 33342 in the 
dark. Samples were analyzed in a Gallios flow cytometer 
and cell cycle profile was analyzed with the Watson 
Pragmatic model.
Apoptosis assay
Apoptosis was assessed in thymocytes by incubation 
with annexin V FITC (diluted 1:20, Immunotools) for 15 
minutes. Then, PI was added and cells were analyzed by 
flow cytometry. Samples were analyzed using a Gallios 
flow cytometer.
Statistics
Data are represented as the mean and standard 
deviation (S.D.) of biological replicates. Statistical 
analysis was performed in GraphPad Prism (La Jolla, CA, 
USA). One-way Analysis of variance with Bonferroni 
post-test was used for multiple comparisons. Differences 
were considered significant when *p < 0.05, **p < 0.01, 
***p < 0.001; n.s. not significant.
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